Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3

DOI:10.33266/1024-6177-2024-69-3-72-76

O.D. Bragina^{1, 2}, M.E. Borodina⁴, V.I. Chernov^{1, 2}, S.M. Deyev^{2, 3},
M.A. Vostrikova¹, A.A. Romanova¹

Assessment of Acute Toxicity of the ^99mTc(CO)3-(HE)3-DARPinG3 in Breast Cancer Patients

¹ National Research Medical Center, Tomsk, Russian

² Research Center “Oncotheranostics”, National Research Tomsk Polytechnic University, Tomsk, Russia

³ M.M. Shemyakin & Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

⁴ National Medical Research Radiological Centre, Moscow, Russia

Contact person: O.D. Bragina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: Study the acute toxicity of the radiopharmaceutical [^99mTc]Tc-(HE)3-G3 in breast cancer patients.

Material and Methods: The study included 10 breast cancer patients (T_1-4N^0-2M₀) with different HER2/neu expression before systemic/surgical treatment, who were injected with 1000 μg of DARPinG3 protein labeled with technetium-99m ([^99mTc]Tc-(HE)3-G3). Throughout the study (48 hours), patients were monitored by medical personnel, during which complaints were assessed, heart rate, blood pressure and body temperature were measured before injection of the radiopharmaceutical, as well as 2, 4, 6, 24 and 48 hours after injection. Additionally, laboratory tests such as general and biochemical blood tests and general urine analysis were performed before injection, 48 hours and 7 days later.

Results: The presence of complaints, as well as the detection of adverse reactions in breast cancer patients included in the study at the time of injection of the radiopharmaceutical [^99mTc]Tc-(HE)3-G3, as well as 2, 4, 6, 24, 48 hours and 7 days after injection were not detected. The measurement of heart rate, body temperature, and blood pressure also showed no pathological abnormalities. According to general and biochemical blood analysis, general urine analysis and ECG results, no abnormalities were found 2, 4, 6, 24 and 48 hours, as well as 7 days after of the radiopharmaceutical [^99mTc]Tc-(HE)3-G3.

Conclusion: The performed studies fully demonstrate the safety of the clinical use of the radiopharmaceutical [^99mTc]Tc-(HE)3-G3 for radionuclide diagnosis of breast cancer patients. The data obtained were confirmed both by the subjective sensations of the patients directly included in the analysis, and by the data of clinical quantitative parameters before the start, as well as 2, 4, 6, 24 and 48 hours after injection of the radiopharmaceutical [^99mTc]Tc-(HE)3-G3.

Keywords: radionuclide diagnostics, scaffold proteins, ^99mTc-DARPinG3, breast cancer, HER2/neu

For citation: Bragina OD, Borodina ME, Chernov VI, Deyev SM, Vostrikova MA, Romanova AA. Assessment of Acute Toxicity of the ^99mTc(CO)3-(HE)3-DARPinG3 in Breast Cancer Patients. Medical Radiology and Radiation Safety. 2024;69(3):72–76. (In Russian). DOI:10.33266/1024-6177-2024-69-3-72-76

References

1. Bragina O, Deyev SM, Chernov VI, Tolmachev VM. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer Acta Naturae. 2022;Apr-Jun;14(2):4–15. DOI: 10.32607/actanaturae.11611. PMID:35923562.

2. Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM. Medical Imaging and Nuclear Medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;Apr;22(4):136-172. DOI: 10.1016/S1470-2045(20)30751-8. PMID: 33676609.

3. Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in Oncology: Current Challenges and Emerging Opportunities. Nat Rev Clin Oncol. 2022;Aug;19(8):534-550. DOI: 10.1038/s41571-022-00652-y. PMID: 35725926.

4. Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, Kirshner JJ, Krop IE, Lin NU, Morikawa A, Patt DA, Perlmutter J, Ramakrishna N, Davidson NE. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022;Aug 10;40(23):2612-2635. DOI: 10.1200/JCO.22.00519. PMID: 35640077.

5. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology. College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997-4013. DOI: 10.1200/JCO.2013.50.9984. PMID: 24101045.

6. Tolmachev V, Orlova A, Sorensen J. The Emerging Role of Radionuclide Molecular Imaging of Her2 Expression in Breast Cancer. Semin Cancer Biol. 2021;72:185-197. DOI: 10.1016/j.semcancer.2020.10.005. PMID: 33465471.

7. Брагина О.Д., Чернов В.И., Гарбуков Е.Ю., Дорошенко А.В., Воробьева А.Г., Орлова А.М., Толмачев В.М. Возможности радионуклидной диагностики HER2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения // Бюллетень сибирской медицины. 2021. Т. 20. №1. С. 23–30. https://doi.org: 10.20538/1682-0363-2021-1-23-30. [Bragina OD, Chernov VI, Garbukov EYu, Doroshenko AV, Vorobyeva AG, Orlova AM, Tolmachev VM. Possibilities of Radionuclide Diagnostics of Her2-Positive Breast Cancer Using Technetium-99m-Labeled Target Molecules: the First Experience of Clinical Use. Bulletin of Siberian Medicine. 2021;20(1):23–30. https://doi.org: 10.20538/1682-0363-2021-1-23-30. (In Russ.)].

8. Tolmachev V, Bodenko V, Oroujeni M, Deyev S, Konovalova E, Schulga AS, Hober S, Bragina OA, Vorobyeva A. Direct in Vivo Comparison of 99mTc-Labeled Scaffold Proteins DARPin G3 and ADAPT6 for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy. International Journal of Molecular Sciences. 2022;Dec;2;23(23):15181. DOI: 10.3390/ijms232315181. PMID: 36499504.

9. Bragina O, Chernov V, Schulga A, Konovalova E, Hober S, Deyev S, Sörensen J, Tolmachev V. Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer. Cancers. 2023;15(12):3149. https://doi.org/10.3390/cancers15123149.

10. Bragina O, von Witting E, Garousi J, Zelchan R, Sandström M, Orlova A, Medvedeva A, Doroshenko A, Vorobyeva A, Lindbo S, Borin J, Tarabanovskaya N, Sörensen J, Hober S, Chernov V, Tolmachev V. Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. J Nucl Med. 2021;Apr;62(4):493-499. DOI: 10.2967/jnumed.120.248799. PMID: 32817142.

11. Bragina O, Chernov V, Larkina M, Rybina A, Zelchan R, Garbukov E, Oroujeni M, Loftenius A, Orlova A, Sörensen J, Frejd FY, Tolmachev V. Phase I Clinical Evaluation of 99mTc-labeled Affibody Molecule for Imaging HER2 Expression in Breast Cancer. Theranostics. 2023;Sep;4;13(14):4858-4871. DOI: 10.7150/thno.86770. PMID: 37771776.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The work was carried out within the framework of the Russian Science Foundation grant No. 22-15-00169 on the topic “Phenotype of BRCA-like tumors in the process of carcinogenesis and treatment.”

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2024. Accepted for publication: 27.02.2024.

Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3

DOI:10.33266/1024-6177-2024-69-3-81-85

Muaayed F. Al-Rawi, Izz K. Abboud, and Nasir A. Al-Awad

Novel Approach Using Transfer Deep Learning for Brain Tumor Prediction

College of Engineering, Mustansiriyah University, Baghdad, Iraq

Contact person: Muaayed F. Al-Rawi, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract:

A brain tumor refers to an abnormal collection or aggregation of cells in the brain that has the potential to be life-threatening owing to the cells’ capacity to penetrate and metastasize to organs that are nearby. It is possible to save lives by making a correct diagnosis of this potentially fatal condition. Within the last several years, there has been a noticeable increase in the functionality of deep learning applications. As a result, improving the module’s architecture leads to better approximations in the monitored configuration. Through the provision of trustworthy datasets, the categorization of tumors via the use of deep learning algorithms has successfully achieved significant progress. The purpose of this article is to use transfer module algorithms for the prediction of brain tumors. These modules include MobileNet, VGG19, InceptionResNetV2, Inception, and DenseNet201. The suggested module uses three main optimizers: Adam, SGD, and RMSprop. The simulation findings indicate that the pre-trained MobileNet module with the RMSprop optimizer outperformed all other evaluated modules. In addition to having the shortest amount of time required for computing, it obtained an accuracy of 99.6 %, a sensitivity of 99.4 %, and a specificity of 100 %. 

Keywords: medical images, brain tumor, machine and deep learning, computer vision, MRI

For citation: Muaayed F. Al-Rawi, Izz K. Abboud, and Nasir A. Al-Awad. Novel Approach Using Transfer Deep Learning for Brain Tumor Prediction. Medical Radiology and Radiation Safety. 2024;69(3):81–85. (In Russian). DOI:10.33266/1024-6177-2024-69-3-81-85

References

1. Mzoughi H., et al. Deep Multi-Scale 3d Convolutional Neural Network (CNN) for MRI Gliomas Brain Tumor Classifcation. J. Digit. Imaging. 2020;33;903–915.

2. Muhammad Sjjad, Salman Khan, Khan Muhammad, Wanqing Wu, Amin Ullah, Sung Wook Baik. Multigrade Brain Tumor Classification Using Deep CNN with Extensive Data Augmentation. Elsevier. Journal of Computational Science. 2019;30:174-182. 

3. Amin Kabir Anaraki, Moosa Ayati, Foad Kazemi. Magnetic Resonance Imaging-Based Brain Tumor Grades Classification and Grading Via Convolutional Neural Networks and Genetic Algorithms. Elsevier. Biocybergenetics and Biomedical Engineering. 2019;39:63-74. 

4. Deepak P.M. Ameer. Brain Tumor Classification Using Deep CNN Features Via Transfer Learning. Elsevier. Computers in Biology and Medicine. 2019;111:1-7. 

5. R.Vimal Kurup, V.Sowmya, K.P.Soman. Effect of Data Pre-processing on Brain Tumor Classification Using Capsulenet. Springer. ICICCT System Reliability, Quality Control, Safety, Maintenance and Management. 2019:110-119.

6. Zar Nawab Khan Swati, Qinghua Zhao, Muhammad Kabir, Farman Ali, Zakir Ali, Saeed Ahmed, Jianfeng Lu. Brain Tumor Classification for MR Images Using Transfer Learning and Finetuning. Elsevier. Computerized Medical Imaging and Graphics. 2019;75:34-46. 

7. Nyoman Abiwinanda, Muhammad Hanif, S. TafwidaHesaputra, Astri Handayani, Tati Rajab Mengko. Brain Tumor Classification Using Convolutional Neural Network. Springer. World Congress on Medical Physics and Biomedical Engineering. 2018:183-189. 

8. F.P.Polly, S.K.Shil, M.A.Hossain, A.Ayman, Y.M.Jang. Detection and Classification of HGG and LGG Brain Tumor Using Machine Learning. IEEE. International Conference on Information Networking (ICOIN), 2018. 

9. Heba Mohsen, El-Sayed A.El-Dahshan, El-Sayed M.El-Horbaty, Abdel-Badeeh M.Salem. Classification Using Deep Learning Neural Networks for Brain Tumors. Elsevier. Future Computing and Informatics Journal. 2018;3:68-71. 

10. Garima Singh, Dr M.A.Ansari. Efficient Detection of Brain Tumor from MRIs Using K-Means Segmentation and Normalized Histogram. IEEE. 1st India International Conference on Information Processing (IICIP), 2016. 

11. Parnian Afshar, Konstantinos N. Plantaniotis, Arash Mohammadi. Capsule Networks for Brain Tumor Classification Based on MRI Images Coarse Tumor Boundaries. IEEE. International Conference on Acoustics, Speech and Signal Processing, 2019.

12. https://www.kaggle.com/datasets/ahmedhamada0/braintumor-detection.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2024. Accepted for publication: 27.02.2024.

Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3

DOI:10.33266/1024-6177-2024-69-3-77-80

I.O. Tomashevsky, O.S. Kornikova

The Importance of SPECT/CT in Simultaneous Assessment
of Calcinosis of Coronary Arteries, Perfusion and Contractile Function of the Myocardium among Men’s with Coronary Heart Disease

Central Clinical Hospital “Russian Railways–Medicine, Moscow, Russia

Contact person: I.O. Tomashevsky, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: To study the frequency of calcinosis of coronary arteries and its effect on myocardial perfusion and contractile function among men’s  with coronary heart disease (CHD).

Material and methods: A survey was conducted  among 1175 men’s aged 30 to 83 years with coronary artery disease (CHD): simultaneous assessment of coronary artery calcinosis, perfusion and contractile function with ^99m Tc-MIBI using SPECT/CT with ECG-synchronization and X-ray radiation attenuation correction, as well as comparison of data with the results of electrocardiography (ECG),  echocardiography (ECHO-CG), clinical and biochemical blood tests.

Results: Of the 1175 men examined using SPECT/CT, coronary artery calcification was detected in 426 (35 %): in the age group over 55 years old – in 142 (12 %), in the age group 46−55 years old – in 200 (17 %), in the age group 27–45 years old – in 74 (6 %). The interval of calcium index indicators in accordance with the Agatston scale was established as follows: at the maximum degree > 400 units – in 87 males (7 % of all examined); at 101−400 units – at 121 (10 %); at 11−100 units – at 162 (14 %); at 1−10 units – in 46
(4 %); with a minimum degree − of 0 units – in 759 men (65 % of all examined). In 34 men of whom 15 had coronary calcification and 19 did not have it, perfusion index (SPB) was either normal or corresponded to the initial degree of decrease in perfusion, and contractile function was slightly impaired, the ejection fraction was not reduced.

Conclusion: The use of SPECT/CT technology with ECG-synchronization and CT-attenuation correction of radiation, in 1175 men with CHD made it possible to detect coronary calcification in 35 %: at the age of 55 years in 12 %, at the age of 46–55 years in 17 %, at the age of 27–45 years – in 6 %. In men with CHD without acute coronary events, both with and without coronary calcinosis, SPB was either normal or corresponded to the initial degree of reduced perfusion, and contractile function was slightly impaired, EF was not reduced. Three years later, in men whose coronary artery calcification was moderate despite its increase to a high degree, the perfusion (SPB) and contractile function indicators did not significantly change, and such indicators did not significantly change in the absence of coronary artery calcification.

Keywords: heart, SPECT/CT, calcinosis of coronary arteries, perfusion, contractile function of the myocardium

For citation: Tomashevsky IO, Kornikova OS. The Importance of SPECT/CT in Simultaneous Assessment of Calcinosis of Coronary Arteries, Perfusion and Contractile Function of the Myocardium among Men’s with Coronary Heart Disease. Medical Radiology and Radiation Safety. 2024;69(3):77–80. (In Russian). DOI:10.33266/1024-6177-2024-69-3-77-80

References

1. Ansheles A.A., Sergienko V.B. Nuclear Cardiology. Moscow Publ., 2021. P. 75-125 (In Russ.).

2. Ansheles A.A., Shulgin D.N., Solomyanyy V.V., Sergienko V.B. Comparison of the Results of Stress Tests, Data of Single-Photon Emission Computed Tomography of Myocardium And Coronarography in Patients with Ischemic Heart Disease. Cardiologicheskiy Vestnik. 2012;VII;2(XIX):10-16 (In Russ.).

3. Rudoy A.S., Zagashvili I.V. Microvascular Angina. Voennaya Meditsina = Military Medicine. 2012;(1):143–8 (In Russ.).

4. Zhuravlev K.N., Vasilyeva E.Yu., Sinitsin V.E., Spector A.V. Calcium Score as a Screening Method for Cardiovascular Disease Diagnosis. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Journal of Cardiology. 2019;12:153-161 (In Russ.) .

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. I.O. Tomashevsky took part in the development of the concept, design, theoretical basis, modification of research methods. O. Kornikova took part in the collection and analysis of literary material, statistical data processing, writing and scientific editing of the text.

Article received: 20.01.2024. Accepted for publication: 27.02.2024.

Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3

DOI:10.33266/1024-6177-2024-69-3-89-90

I.V. Ivanov^{1, 2}, V.N. Vyalykh¹

In Memory of Radiotoxicologist Yuri Alexandrovich Klassovsky 
for the 100th Anniversary of his Birth on 01/15/1924–04/27/1982

¹ N.F. Izmerov Research Institute of Occupational Medicine, Moscow, Russia

² State Scientific-Research Taste Institute of Military Medicine, Saint-Petersburg, Russia

Contact person: I.V. Ivanov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

For citation: Ivanov IV, Vyalykh VN. In Memory of Radiotoxicologist Yuri Alexandrovich Klassovsky. 100th Anniversary of his Birth on 01/15/1924–04/27/1982. Medical Radiology and Radiation Safety. 2024;69(3):89–90. (In Russian). DOI:10.33266/1024-6177-2024-69-3-89-90

References

1. Klassovsky Yu.A. Regeneration and Tumor Formation in the Thyroid Gland after Irradiation with Iodine-131. Vosstanovitelnyye Protsessy pri Porazhenii: Organizma Ioniziruyushchey Radiatsiyey = Restorative Processes when the Body Is Damaged by Ionizing Radiation. Conference Materials. Moscow, 1966. P. 93–95 (In Russ.).

2. Klassovsky Yu.A. Dependence of the Effect of Radiation on the Dose Distribution in the Histological Structures of the Thyroid Gland. Radiatsionnaya Endokrinologiya = Radiation Endocrinology. Obninsk. 1967. P. 40–42 (In Russ.).

3. Klassovsky Yu.A. On the Influence of the Dose Microdistribution Factor on the Effect of Irradiation of the Thyroid Gland. Bulletin of the Academy of Medical Sciences. 1967;12:25–30 (In Russ.).

4. Klassovsky Yu.A., Vasilenko I.Ya., Terekhov N.L.. Methods and Results of Assessing the Equivalent Dose of Irradiation of the Thyroid Gland of Experimental Animals and Humans with Various Radioactive Isotopes of Iodine and Their Mixtures. Radiobiologicheskiy Eksperiment i Chelovek = Radiobiological Experiment and Man. Moscow, Atomizdat, 1970. P. 155–167. (In Russ.).

5. Klassovsky Yu.A. Questions of the Etiology and Pathogenesis of Thyroid Tumors During Internal Irradiation with Radioactive Iodine Isotopes. Raspredeleniye, Kinetika Obmena i Biologicheskoye Deystviye Radioaktivnykh Izotopov Yoda = Distribution, Kinetics of Metabolism and Biological Effect of Radioactive Iodine Isotopes. Moscow, Meditcina, 1970. P. 134–143 (In Russ.).

6. Klassovsky Yu.A. Effects of external and internal exposures that arise from the fallout processes of nuclear explosions. Some questions of aetiology and pathogenesis. Dejstvie vneshnego i vnutrennego obluchenij v usloviyah formirovaniya radioaktivnyh sledov yadernyh vzryvov. Voprosy etiologii i patogeneza. Moscow, MDV Publishing House, 2024. 360 p. (In Russ.).

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2024. Accepted for publication: 27.02.2024.